Riskpilot← Back to searchSign inGet full accessDevelo ApS
APSActiveCVR 43401548Naverland 4Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2022— employeeshttps://sundvik.dk
Revenue 2024
DKK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
DKK 0
-100% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK 0 | — |
| Net profit | DKK 0 | -100% |
| Total assets | DKK 40K | +0% |
| Equity | DKK 40K | +0% |
| Employees | — | — |
Legal name
Develo ApS
CVR number
43401548
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
11. juli 2022
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør alene.
Company purpose
Selskabets formål Selskabets formål er at drive erhvervsmæssig virksomhed inden for online handel, distribution og detailhandel af sundhedsrelaterede produkter, herunder varer til personlig pleje, kosttilskud, produkter til gravide, lægemidler og medicinske hjælpemidler, udvalgte føde- og drikkevarer samt produkter til dyr.
Selskabet må endvidere drive detailhandel med informations- og kommunikationsudstyr samt enhver dermed beslægtet virksomhed.
Selskabet er ikke et apotek og forhandler ikke receptpligtige lægemidler.
Address
Naverland 4
Phone
+4542243489
Email
sundvik.dk@gmail.com
Website
https://sundvik.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | -7 | 0 | 0 |
| Staff expenses | -0 | -0 | -0 |
| EBITDA | -7 | 0 | 0 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | -7 | 0 | 0 |
| Net financials | 0 | 7 | 0 |
| Profit before tax | -7 | 7 | 0 |
| Tax | -0 | -0 | -0 |
| Net profit | -7 | 7 | 0 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 33 | 40 | 40 |
| Equity | 33 | 40 | 40 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 |
| Total debt | 0 | 0 | 0 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20222024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20222024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20222024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RA Chief Executive Officer | Chief Executive Officer | 2024 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2022 | |
| Individual | 50–66.65% | 50–66.65% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DR2 Holding ApS
Develo ApS Board members of Develo ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rasool Alizadeh Fakouri | Chief Executive Officer | 0 companies |